Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 15 | 2024 | 2882 | 2.560 |
Why?
|
Radiotherapy, Intensity-Modulated | 10 | 2023 | 801 | 2.410 |
Why?
|
Radiation Pneumonitis | 2 | 2024 | 102 | 1.680 |
Why?
|
Radiation Injuries | 8 | 2024 | 1182 | 1.300 |
Why?
|
Nasopharyngeal Neoplasms | 2 | 2019 | 286 | 1.070 |
Why?
|
Radiodermatitis | 3 | 2022 | 58 | 1.020 |
Why?
|
Radiotherapy Dosage | 10 | 2023 | 2896 | 0.990 |
Why?
|
Breast Neoplasms | 11 | 2023 | 21017 | 0.870 |
Why?
|
Radiosurgery | 2 | 2023 | 1342 | 0.860 |
Why?
|
Carcinoma | 3 | 2023 | 2330 | 0.840 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5246 | 0.770 |
Why?
|
Dermatitis | 1 | 2023 | 200 | 0.760 |
Why?
|
Lupus Erythematosus, Discoid | 1 | 2021 | 61 | 0.750 |
Why?
|
Lung Neoplasms | 7 | 2024 | 13245 | 0.740 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2024 | 9273 | 0.740 |
Why?
|
Nausea | 3 | 2024 | 677 | 0.730 |
Why?
|
Lupus Erythematosus, Cutaneous | 1 | 2021 | 73 | 0.720 |
Why?
|
Glycosyltransferases | 1 | 2021 | 117 | 0.720 |
Why?
|
Deglutition Disorders | 3 | 2024 | 625 | 0.720 |
Why?
|
Vomiting | 3 | 2024 | 651 | 0.720 |
Why?
|
Craniopharyngioma | 1 | 2023 | 277 | 0.710 |
Why?
|
Mitochondrial Membrane Transport Proteins | 1 | 2021 | 158 | 0.690 |
Why?
|
Health Physics | 1 | 2019 | 30 | 0.670 |
Why?
|
Fibrosarcoma | 1 | 2021 | 308 | 0.650 |
Why?
|
Otorhinolaryngologic Neoplasms | 1 | 2018 | 26 | 0.630 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 9 | 2024 | 1659 | 0.620 |
Why?
|
Fanconi Anemia | 1 | 2020 | 324 | 0.590 |
Why?
|
Chordoma | 1 | 2020 | 346 | 0.580 |
Why?
|
Free Tissue Flaps | 1 | 2022 | 327 | 0.580 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2023 | 4023 | 0.570 |
Why?
|
Radiation Oncology | 2 | 2022 | 563 | 0.560 |
Why?
|
Leiomyosarcoma | 1 | 2021 | 424 | 0.560 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 1840 | 0.530 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2023 | 345 | 0.490 |
Why?
|
Radiotherapy, Conformal | 1 | 2018 | 549 | 0.490 |
Why?
|
Photons | 1 | 2019 | 581 | 0.490 |
Why?
|
Ureteral Neoplasms | 1 | 2015 | 110 | 0.480 |
Why?
|
Organs at Risk | 3 | 2023 | 358 | 0.470 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1313 | 0.470 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2023 | 555 | 0.470 |
Why?
|
Brachytherapy | 1 | 2022 | 1236 | 0.460 |
Why?
|
Protons | 1 | 2019 | 1112 | 0.440 |
Why?
|
Radiotherapy | 6 | 2024 | 1504 | 0.430 |
Why?
|
Soft Tissue Neoplasms | 2 | 2024 | 1152 | 0.430 |
Why?
|
Neoplasms, Second Primary | 1 | 2021 | 1056 | 0.430 |
Why?
|
Brain Stem | 1 | 2018 | 857 | 0.430 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2024 | 1791 | 0.420 |
Why?
|
Receptor, erbB-2 | 1 | 2023 | 2553 | 0.410 |
Why?
|
Antiemetics | 2 | 2024 | 187 | 0.390 |
Why?
|
Dysgeusia | 2 | 2023 | 15 | 0.390 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 346 | 0.380 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2023 | 262 | 0.360 |
Why?
|
Repressor Proteins | 1 | 2021 | 2980 | 0.350 |
Why?
|
Piperazines | 1 | 2020 | 2511 | 0.340 |
Why?
|
Pneumonia | 1 | 2021 | 2129 | 0.330 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2021 | 2159 | 0.320 |
Why?
|
Xerostomia | 2 | 2019 | 94 | 0.320 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3609 | 0.320 |
Why?
|
Humans | 54 | 2024 | 758381 | 0.320 |
Why?
|
Pyridines | 1 | 2020 | 2860 | 0.310 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5629 | 0.290 |
Why?
|
Lung | 6 | 2024 | 9985 | 0.290 |
Why?
|
Tumor Burden | 2 | 2024 | 1893 | 0.280 |
Why?
|
Retrospective Studies | 15 | 2023 | 80170 | 0.280 |
Why?
|
Neoplasms | 3 | 2024 | 22030 | 0.250 |
Why?
|
France | 3 | 2024 | 499 | 0.250 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2024 | 2004 | 0.240 |
Why?
|
Mastectomy | 2 | 2023 | 1832 | 0.230 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11709 | 0.230 |
Why?
|
Prospective Studies | 8 | 2024 | 54136 | 0.220 |
Why?
|
Observer Variation | 3 | 2024 | 2600 | 0.200 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36285 | 0.200 |
Why?
|
Paraganglioma | 1 | 2023 | 142 | 0.190 |
Why?
|
Tomography, X-Ray Computed | 7 | 2024 | 20500 | 0.190 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2023 | 240 | 0.180 |
Why?
|
Retreatment | 1 | 2022 | 596 | 0.180 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2021 | 117 | 0.180 |
Why?
|
Mouth | 1 | 2023 | 380 | 0.180 |
Why?
|
Vertebroplasty | 1 | 2021 | 78 | 0.170 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2943 | 0.170 |
Why?
|
Myelitis | 1 | 2019 | 49 | 0.170 |
Why?
|
Bone Cements | 1 | 2021 | 324 | 0.160 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2021 | 243 | 0.160 |
Why?
|
Dental Care | 1 | 2022 | 279 | 0.160 |
Why?
|
Female | 20 | 2024 | 390316 | 0.160 |
Why?
|
Sacrum | 1 | 2020 | 277 | 0.160 |
Why?
|
Muscles | 1 | 2023 | 1579 | 0.150 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2019 | 102 | 0.150 |
Why?
|
Surgical Flaps | 2 | 2024 | 1669 | 0.150 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2021 | 546 | 0.150 |
Why?
|
Carboplatin | 2 | 2022 | 788 | 0.140 |
Why?
|
Reproducibility of Results | 4 | 2024 | 20052 | 0.140 |
Why?
|
Mastectomy, Segmental | 1 | 2022 | 972 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 480 | 0.140 |
Why?
|
Neutropenia | 1 | 2020 | 884 | 0.120 |
Why?
|
Aged | 10 | 2024 | 168217 | 0.120 |
Why?
|
Telomerase | 1 | 2019 | 745 | 0.120 |
Why?
|
Hypothyroidism | 1 | 2019 | 665 | 0.120 |
Why?
|
Etoposide | 1 | 2015 | 630 | 0.120 |
Why?
|
Uncertainty | 1 | 2019 | 751 | 0.120 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 8530 | 0.110 |
Why?
|
Sarcoma | 1 | 2024 | 1785 | 0.100 |
Why?
|
Adult | 9 | 2024 | 219916 | 0.100 |
Why?
|
Hearing Loss | 1 | 2019 | 780 | 0.100 |
Why?
|
Middle Aged | 10 | 2024 | 219560 | 0.100 |
Why?
|
Quality of Life | 2 | 2024 | 13286 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2021 | 2912 | 0.090 |
Why?
|
Aged, 80 and over | 3 | 2023 | 58681 | 0.090 |
Why?
|
Young Adult | 4 | 2023 | 58808 | 0.090 |
Why?
|
Lymph Nodes | 2 | 2019 | 3485 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3527 | 0.090 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2022 | 2016 | 0.090 |
Why?
|
Remission Induction | 1 | 2015 | 2388 | 0.090 |
Why?
|
Male | 10 | 2024 | 358742 | 0.090 |
Why?
|
RNA | 1 | 2019 | 2716 | 0.080 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4901 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6821 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2019 | 2379 | 0.080 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6457 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2019 | 3561 | 0.070 |
Why?
|
Stem Cells | 1 | 2019 | 3521 | 0.070 |
Why?
|
Adenocarcinoma | 1 | 2023 | 6313 | 0.060 |
Why?
|
Radiometry | 2 | 2021 | 813 | 0.060 |
Why?
|
Prognosis | 3 | 2021 | 29558 | 0.060 |
Why?
|
Survival Rate | 1 | 2019 | 12721 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8611 | 0.060 |
Why?
|
Treatment Outcome | 2 | 2021 | 64379 | 0.060 |
Why?
|
Osteoradionecrosis | 1 | 2024 | 51 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5691 | 0.050 |
Why?
|
Incidence | 1 | 2021 | 21273 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 8981 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5797 | 0.050 |
Why?
|
Risk Assessment | 1 | 2024 | 23883 | 0.050 |
Why?
|
Skull Base | 1 | 2023 | 291 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17768 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2022 | 13591 | 0.040 |
Why?
|
Linear Energy Transfer | 1 | 2020 | 152 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2019 | 881 | 0.040 |
Why?
|
Metals | 1 | 2022 | 717 | 0.040 |
Why?
|
Postoperative Care | 1 | 2024 | 1471 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39060 | 0.040 |
Why?
|
Genes, BRCA1 | 1 | 2021 | 765 | 0.040 |
Why?
|
Fibrosis | 1 | 2024 | 2038 | 0.030 |
Why?
|
Water | 1 | 2022 | 1402 | 0.030 |
Why?
|
Neck | 1 | 2020 | 731 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1728 | 0.030 |
Why?
|
Adolescent | 1 | 2023 | 87888 | 0.030 |
Why?
|
Head | 1 | 2020 | 921 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2024 | 2634 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2509 | 0.030 |
Why?
|
Societies, Medical | 1 | 2024 | 3891 | 0.030 |
Why?
|
Consensus | 1 | 2021 | 3099 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4244 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2796 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2019 | 14354 | 0.010 |
Why?
|
Age Factors | 1 | 2021 | 18357 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16886 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22006 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13959 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29915 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41252 | 0.010 |
Why?
|
Mice | 1 | 2019 | 81107 | 0.010 |
Why?
|
Animals | 1 | 2019 | 167777 | 0.000 |
Why?
|
Concepts
(163)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_